Related Experiment Video
Updated: Aug 15, 2026
Generation of Immature, Mature and Tolerogenic Dendritic Cells with Differing Metabolic Phenotypes
Published on: June 22, 2016
Generation of human dendritic cells/Langerhans cells from circulating CD34+ hematopoietic progenitor cells
D Strunk1, K Rappersberger, C Egger
1Division of Immunology, Allergy and Infectious Diseases, Vienna International Research Cooperation Center (VIRCC), University of Vienna Medical School, Austria.
Insights
Researchers developed a new method to generate human dendritic cells (DCs) and Langerhans cells (LCs) from blood stem cells. These in vitro generated cells show potential for use in vaccines to boost immune responses.
Area of Science:
- Immunology
- Cell Biology
- Biotechnology
Background:
- Human Langerhans cells (LCs) are crucial CD1a+ dendritic cells (DCs) for immune responses.
- Current isolation methods limit DC/LC numbers, hindering their use as immunogens.
- Generating sufficient DCs/LCs is vital for developing novel vaccines and immunotherapies.
Purpose of the Study:
- To develop an efficient procedure for generating human dendritic cells (DCs) and Langerhans cells (LCs) from CD34+ hematopoietic progenitor cells (HPCs).
- To characterize the phenotype and function of in vitro generated DCs/LCs.
- To assess the potential of these cells as immunogens for vaccination purposes.
Main Methods:
- Isolation and purification of CD34+ hematopoietic progenitor cells (HPCs) from peripheral blood.
- In vitro culture of HPCs with granulocyte-macrophage colony-stimulating factor (GM-CSF) and tumor necrosis factor (TNF)-alpha, with and without interleukin (IL)-4.
- Flow cytometry analysis for cell surface markers (CD1a, CD45, CD68, CD3, CD19, CD56, CD14) and transmission electron microscopy for Birbeck granules (BG).
Main Results:
- Culture with GM-CSF and TNF-alpha generated leukocytes, including CD1a+ cells (12%) with antigen-presenting capabilities.
- These CD1a+ cells included LCs (with Birbeck granules), monocytes, and dendritic-shaped cells.
- Addition of IL-4 increased the percentage of CD1a+ cells (24%) but reduced overall yield and monocyte development.
- In vitro generated CD1a+ HPC-derived cells potently stimulated the primary mixed leukocyte reaction.
Conclusions:
- A novel procedure effectively generates human dendritic cells (DCs) and Langerhans cells (LCs) from peripheral blood hematopoietic progenitor cells (HPCs).
- The generated CD1a+ cells possess potent antigen-presenting cell activity, stimulating mixed leukocyte reactions.
- These in vitro derived DCs/LCs are promising candidates for future vaccine development and immunotherapy applications.
Abstract:
Human Langerhans cells (LC) are CD1a+ dendritic cells (DC) that function as potent antigen-presenting cells for primary and secondary immune responses. Limitations in DC/LC numbers, imposed by difficult and tedious isolation procedures, have so far precluded their use as immunogens in the generation and/or augmentation of host responses against various pathogens. Therefore, we have developed a procedure for the generation of human DC/LC from CD34+ hematopoietic progenitor cells (HPC) isolated (mean: 0.7 x 10(6)/ buffy coat and 2.6 x 10(6)/leukapheresis product) and purified ( > 95%) from the peripheral blood of healthy adults. In vitro stimulation of these cells with granulocyte-macrophage colony-stimulating factor (GM-CSF) and tumor necrosis factor (TNF)-alpha led to their vigorous proliferation and differentiation resulting in the emergence of CD45+/CD68+/CD3-/CD19-/CD56- leukocytes some of which (mean: 12%) express CD1a and exhibit anti-CD4 and anti-major histocompatibility complex (MHC) class II reactivity. These CD1a- leukocytes include (1) LC as evidenced by the presence of Birbeck granules (BG), (2) CD14+ monocytes, and (3) Birbeck granule-negative cells with a dendritic morphology. Addition of interleukin (IL)-4 to the cytokine cocktail interfered with the development of monocytes and led to a reduction in the overall yield but, on the other hand, resulted in an increased percentage of CD1a+ cells (mean: 24%) among all cells generated. In vitro generated CD1a+, but not CD1a- HPC-derived cells are potent stimulators of the primary mixed leukocyte reaction and, as such, promising candidates for vaccination purposes.
